StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Valeant (VRX) Provides Plenty to Support Bullish Thesis - Guggenheim
August 9, 2016 10:25 AM
Guggenheim analyst Louise Chen reiterated a Buy rating and $55 price target on Valeant Pharmaceuticals (NYSE: VRX) following a Q2 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Valeant (VRX) PT Bumped to $22 at Piper Jaffray; Keeps Lowest Rating
August 10, 2016 7:04 AM
Valeant Pharma (VRX) Pushes to Session Highs
August 9, 2016 2:26 PM
Valeant looks to sell billions in assets to cut debt, stock soars
August 9, 2016 9:52 AM
Valeant Pharma (VRX) Adds to Early Gains
August 9, 2016 9:47 AM
Valeant Pharma (VRX) Misses Q2 EPS by 8c, Reaffirms Guidance; Will Divest Ruconest Rights in N.A.
August 9, 2016 6:01 AM
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 9, 2016 6:00 AM
